TC Medical(SH:600763) Sou Hu Cai Jing·2025-10-29 13:49Core Viewpoint - Tongce Medical (600763) shows a stable performance with a slight increase in stock price and mixed capital flow, indicating potential investor interest despite some outflows from institutional and speculative funds [1][2]. Group 1: Stock Performance - As of October 29, 2025, Tongce Medical's stock closed at 42.99 yuan, up by 0.99% with a turnover rate of 1.27% and a trading volume of 56,600 hands, resulting in a transaction amount of 242 million yuan [1]. - Over the past five days, the stock has experienced fluctuations in capital flow, with a net outflow of 662.74 million yuan on October 29, 2025, while retail investors saw a net inflow of 757.1 million yuan [2]. Group 2: Financial Metrics - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56%, and a net profit attributable to shareholders of 514 million yuan, up by 3.16% [3]. - The company's third-quarter performance included a single-quarter main revenue of 842 million yuan, reflecting a 2.34% year-on-year increase, and a net profit of 192 million yuan, up by 2.31% [3]. - Key financial ratios include a total market value of 19.229 billion yuan, a net asset of 4.703 billion yuan, and a net profit margin of 26.91%, which is significantly higher than the industry average [3]. Group 3: Institutional Ratings - In the last 90 days, nine institutions have rated Tongce Medical, with seven giving a "buy" rating and two an "increase" rating, indicating positive sentiment among analysts [4]. - The average target price set by institutions over the past 90 days is 52.01 yuan, suggesting potential upside from the current trading price [4].